Carbiotix has always had the ambition to leverage its consumer platform to both develop and deliver therapeutics that will address a range of leading metabolic and chronic diseases, as well as accelerate gut health improvements across the general population. After a successful validation of Carbiotix consumer platform during 2018, the company is now transitioning into this next exciting phase and will be ramping up exploration and pre-clinical development activities in the second half of 2018. We look forward to sharing more about our therapeutic development activities in the near future, as well as our unique discovery and delivery platform.